We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

VEDA LAB

VEDALAB focuses on the development, production and marketing of in vitro immunodiagnostic reagents and instruments. I... read more Featured Products: More products

Download Mobile App





Vedalab Exhibits Rapid Diagnostic Tests

By LabMedica International staff writers
Posted on 11 Nov 2024

Vedalab (Cerisé, France) is showcasing its wide range of rapid diagnostic tests at the MEDICA exhibition from November 11th to 14th, 2024 being held in Dusseldorf, Germany. More...

Vedalab offers a wide range of immunochromatographic rapid tests which are being highlighted at the trade fair. This includes the new Vitamin D-CHECK-1 immunochromatographic rapid test for the quantitative determination of Vitamin D in plasma or serum samples and the Toxo IgG-CHECK-1 immunochromatographic rapid test for the qualitative detection of IgG antibodies to Toxoplasma gondii in whole blood, plasma or serum samples. Vedalab’s quantitative rapid tests are designed for use on its EASY READER+ instrument showcased at MEDICA 2024. This POC reader enables quantitative measurements from finger-prick whole blood samples using rapid lateral flow tests. The instrument includes the most advanced and up-to-date technologies such as touch screen, enhanced memory, and internet upgrading. The EASY READER+ and quantitative rapid tests are designed for healthcare professionals, for use in physician’s offices, clinical laboratories, and online pharmacies, and for consumers through organizations that provide diagnostic information.

Vedalab’s EASY READER+ and quantitative rapid tests are widely used as screening tools for various medical conditions and diseases. Vedalab is also highlighting its range of immunochromatographic rapid tests for the quantitative detection of AFP (alpha-fetoprotein), beta chain specific hCG (human chorionic gonadotrophin), C-peptide, CA 125 (ovarian cancer antigen), Cancer Antigen 15-3 (CA 15-3), Cancer Antigen 19-9 (CA 19-9), Calprotectin, CEA (carcinoembryonic antigen), Creatine Kinase MB isoenzyme, Cortisol, C-reactive protein, and D-DIMER in whole blood, serum, urine or plasma samples. These tests generate accurate, rapid, and cost-effective diagnostic information for acute and chronic conditions affecting men's and women's health at various stages of life.

Related Links:
Vedalab


New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The portable platform could address diagnostic gaps for tuberculosis testing in clinics without access to advanced laboratory infrastructure (photo credit: Shutterstock)

Portable Test Detects Tuberculosis from Tongue Swabs in 30 Minutes

Despite decades of effective drug regimens, tuberculosis remains the leading cause of death from an infectious disease, driven in part by limited access to accurate, rapid testing. Conventional diagnostics... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.